Additional file 1 of Tumor residue in patients with stage II–IVA nasopharyngeal carcinoma who received intensity-modulated radiation therapy: development and validation of a prediction nomogram integrating postradiotherapy plasma Epstein–Barr virus deoxyribonucleic acid, clinical stage, and radiotherapy dose
Creators: name: Huang, Ying-Ying
name: Zhou, Jia-Yu
name: Zhan, Ze-Jiang
name: Ke, Liang-Ru
name: Xia, Wei-Xiong
name: Cao, Xun
name: Cai, Zhuo-Chen
name: Deng, Ying
name: Chen, Xi
name: Zhang, Lu-Lu
name: Huang, Hao-Yang
name: Guo, Xiang
name: Lv, Xing
Publisher: name: figshare
Year: 2023
Subjects: Medicine
Biological Sciences not elsewhere classified
Mathematical Sciences not elsewhere classified
Developmental Biology
Cancer

description: Additional file 1: sTable 1. Clinical characteristics of patients in the development and validation cohorts. sTable 2. Distribution of pretreatment plasma EBV DNA by TNM stage (AJCC 8th edition). sTable 3. Distribution of postradiotherapy plasma EBV DNA by TNM stage (AJCC 8th edition). sTable 4. Comparison of AUC and OR of residue at different level of pretreatment EBV DNA in the development cohort (n=736). sTable 5. Comparison of AUC and OR of residue at different level of postradiotherapy EBV DNA in the development cohort (n=736). sTable 6. Pretreatment and postradiotherapy levels of EBV DNA in all patients (n=1050). sFigure 1. Kaplan-Meier curves for overall survival (A), progression-free survival (B), locoregional recurrence-free survival (C) and distant metastasis-free survival (D) in patients stratified by residual tumor type (n=190). sFigure 2. Pretreatment (A) and postradiotherapy (B) plasma EBV DNA levels by TNM stage (AJCC 8th edition) in the development cohort (n=736). sFigure 3. Kaplan-Meier curves for overall survival (A), progression-free survival (B), locoregional recurrence-free survival (C) and distant metastasis-free survival (D) in all patients stratified by pretreatment plasma EBV DNA level (n=1050). sFigure 4. Kaplan-Meier curves for overall survival (A), progression-free survival (B), locoregional recurrence-free survival (C) and distant metastasis-free survival (D) in all patients stratified by postradiotherapy plasma EBV DNA level (n=1050). sFigure 5. Comparison of six models using area under the receiver operating characteristic curve calculated for the development cohort (n=736). sFigure 6. Kaplan-Meier curves for locoregional recurrence-free survival (A) and distant metastasis-free survival (B) in development cohort stratified by predicted risk in tumor residue (n=736). sFigure 7. Kaplan-Meier curves for locoregional recurrence-free survival (A) and distant metastasis-free survival (B) in validation cohort stratified by predicted risk in tumor residue (n=314). sFigure 8. Kaplan-Meier curves for overall survival (A), progression free-survival (B), locoregional recurrence-free survival (C) and distant metastasis-free survival (D) in patients with residue from development cohort stratified by predicted risk in tumor residue (n=122). sFigure 9. Kaplan-Meier curves for overall survival (A), progression free-survival (B), locoregional recurrence-free survival (C) and distant metastasis-free survival (D) in patients with residue from validation cohort stratified by predicted risk in tumor residue (n=68).